Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Embracing the latest technology trends, LPH 1.0 represents a significant leap forward, with an upgrade to HTML5 browser-based technology. This advancement ...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth a...
Biopharma M&A in 2023 Biopharma M&A activity has witnessed a decisive rebound in 2023, with aggregate deal value up by 79% vs. 2022 to reach ~$152...
“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...
The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults1.There...
The company is set to introduce multi-omics capabilities on the AVITI platform, along with enhancements to the first commercial Q50 kit and a host of workf...
he added capacity will further enhance WuXi Biologics’ commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people...
HistoSonics, , the manufacturer of the non-invasive Edison® Histotripsy System, announced a patient from the University of Rochester Medical Cent...
“It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s pr...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
© 2025 Biopharma Boardroom. All Rights Reserved.
